The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PYX-106-101
Previous Study | Return to List | Next Study

Study of PYX-106 in Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05718557
Recruitment Status : Recruiting
First Posted : February 8, 2023
Last Update Posted : April 5, 2024
Sponsor:
Information provided by (Responsible Party):
Pyxis Oncology, Inc

Brief Summary:
The primary objective of this study is to determine the recommended dose(s) of PYX-106 in participants with relapsed/refractory solid tumors.

Condition or disease Intervention/treatment Phase
Solid Tumor Drug: PYX-106 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX-106 in Subjects With Advanced Solid Tumors
Actual Study Start Date : May 23, 2023
Estimated Primary Completion Date : April 2024
Estimated Study Completion Date : August 2025

Arm Intervention/treatment
Experimental: PYX-106 Dose Escalation
Participants will receive escalating doses of PYX-106 to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of PYX-106, and to determine the recommended dose(s).
Drug: PYX-106
Intravenous (IV) infusion




Primary Outcome Measures :
  1. Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) [ Time Frame: Day 1 to Day 28 ]
  2. Number of Participants Who Experience an Adverse Event (AE) [ Time Frame: Day 1 up to approximately 2 years ]
    Type, incidence, seriousness and causality of AEs based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Any clinically significant changes in clinical laboratory parameters, vital signs, and electrocardiogram (ECG) parameters will be recorded as AEs.


Secondary Outcome Measures :
  1. Maximum Concentration (Cmax) of PYX-106 [ Time Frame: Day 1 up to approximately 2 years ]
  2. Time to Maximum Concentration (Tmax) of PYX-106 [ Time Frame: Day 1 up to approximately 2 years ]
  3. Area Under the Time Concentration Curve from Time 0 to the Last Quantifiable Concentration (AUC0-t) of PYX-106 [ Time Frame: Day 1 up to approximately 2 years ]
  4. Area Under the Time Concentration Curve from Time 0 to the End of the Dosing Interval (AUCtau) of PYX-106 [ Time Frame: Day 1 up to approximately 2 years ]
  5. Area Under the Time Concentration Curve from Time 0 Extrapolated to Infinity (AUC0-inf) of PYX-106 [ Time Frame: Day 1 up to approximately 2 years ]
  6. Half Life (t1/2) of PYX-106 [ Time Frame: Day 1 up to approximately 2 years ]
  7. Objective Response Rate (ORR) [ Time Frame: Day 1 up to approximately 2 years ]
  8. Duration of Response (DOR) [ Time Frame: Day 1 up to approximately 2 years ]
  9. Progression Free Survival (PFS) [ Time Frame: Day 1 up to approximately 2 years ]
  10. Disease Control Rate (DCR) [ Time Frame: Day 1 up to approximately 2 years ]
  11. Time to Response [ Time Frame: Day 1 up to approximately 2 years ]
  12. Overall Survival (OS) [ Time Frame: Day 1 up to approximately 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Participants with histologically or cytologically confirmed solid tumors who have relapsed, been non-responsive, or have developed disease progression through standard therapy.
  2. Histologically or cytologically confirmed solid tumors (see details below):

    For the dose escalation, the following solid tumors are allowed in participants who have developed disease progression through standard therapy and in participants for whom standard of care therapy that prolongs survival is unavailable or unsuitable, which include non-small cell lung cancer without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.

  3. Clinical sites must provide archived tissue or conduct fresh tumor biopsy (formalin-fixed paraffin-embedded [FFPE]; enough to create a minimum of 14 slides). Fresh biopsy pre-treatment is preferred, archival tissue (the most recent available) is acceptable if fresh biopsy is not performed at Screening. Both fresh and archival tissue samples must be collected by core needle biopsy or surgical resection. Fine needle aspirates are not permitted.
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.
  5. Participant must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumor (RECIST) Version 1.1 criteria (by local Investigator). Participant must have radiographic evidence of disease progression based on RECIST criteria following the most recent line of treatment.
  6. Life expectancy of >3 months, in the opinion of the Investigator.

Exclusion Criteria:

  1. History of another malignancy except for the following: adequately treated local basal cell or squamous cell carcinoma of the skin; in situ cervical carcinoma, adequately treated; other adequately treated Stage 1 or 2 cancers currently in complete remission; any other cancer that has been in complete remission for >2 years or cancer of low risk of recurrence; or any treated or monitored indolent cancer that is unlikely to cause mortality in 5 years.
  2. Known symptomatic brain metastases requiring >10 mg/day of prednisolone (or its equivalent) at the time of signing informed consent.
  3. Continuance of toxicities due to prior anti-cancer agents that do not recover to Grade 1 prior to start of PYX-106 treatment, except for alopecia or endocrine deficiencies treated with stable hormone replacement therapy.
  4. Presence of Grade ≥2 peripheral neuropathy.
  5. Major surgery within 4 weeks prior to the start of PYX-106 treatment, as defined by the Investigator.
  6. Received palliative radiation therapy within 14 days prior to the start of PYX-106 treatment.
  7. Received a live vaccine within 28 days prior to the first dose of study treatment and while participating in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05718557


Contacts
Layout table for location contacts
Contact: Chalyse Bush (339) 545 8252 clinicaltrials@pyxisoncology.com

Locations
Show Show 17 study locations
Sponsors and Collaborators
Pyxis Oncology, Inc
Layout table for additonal information
Responsible Party: Pyxis Oncology, Inc
ClinicalTrials.gov Identifier: NCT05718557    
Other Study ID Numbers: PYX-106-101
2022-002306-24 ( EudraCT Number )
First Posted: February 8, 2023    Key Record Dates
Last Update Posted: April 5, 2024
Last Verified: April 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pyxis Oncology, Inc:
Solid Tumors
Advanced Solid Tumors
PYX-106
Relapsed Solid Tumors
Refractory Solid Tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms